Generic-Drug Fee Plan at FDA Caught Up in Budget Impasse

A $300 million program to speed U.S. reviews of generic drugs made by Mylan Inc., Teva Pharmaceutical Industries Ltd. and other companies may not start as planned on Oct. 1 because of a budget impasse in Congress.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.